Aptevo Therapeutics Inc (APVO) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Aptevo Therapeutics Inc stock (APVO) is currently trading at $4.22. Aptevo Therapeutics Inc PS ratio (Price-to-Sales) is 1.61. Analyst consensus price target for APVO is $21.00. WallStSmart rates APVO as Sell.
- APVO PE ratio analysis and historical PE chart
- APVO PS ratio (Price-to-Sales) history and trend
- APVO intrinsic value — DCF, Graham Number, EPV models
- APVO stock price prediction 2025 2026 2027 2028 2029 2030
- APVO fair value vs current price
- APVO insider transactions and insider buying
- Is APVO undervalued or overvalued?
- Aptevo Therapeutics Inc financial analysis — revenue, earnings, cash flow
- APVO Piotroski F-Score and Altman Z-Score
- APVO analyst price target and Smart Rating
Aptevo Therapeutics Inc
📊 No data available
Try selecting a different time range
APVO Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Aptevo Therapeutics Inc (APVO)
APVO trades at a significant discount to its Graham intrinsic value of $52755.76, offering a 100% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Aptevo Therapeutics Inc (APVO) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/sales, price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Aptevo Therapeutics Inc (APVO) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Paying $1.61 for every $1 of annual revenue
Supporting Valuation Data
Aptevo Therapeutics Inc (APVO) Areas to Watch (4)
Company is destroying shareholder value
Revenue declining -100.00%, a shrinking business
Very low institutional interest at 2.05%
Micro-cap company with very limited liquidity and high volatility
Aptevo Therapeutics Inc (APVO) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 2 register as strengths (avg 9.0/10) while 4 fall into concern territory (avg 1.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Price/Sales. Valuation metrics including Price/Sales (1.61), Price/Book (0.26) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Revenue Growth, Institutional Own.. Growth concerns include Revenue Growth at -100.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -242.70%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -242.70% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -100.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Revenue Growth are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
APVO Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
APVO's Price-to-Sales ratio of 1.61x trades at a 16% premium to its historical average of 1.39x (79th percentile). The current valuation is 88% below its historical high of 13.28x set in Dec 2020, and 7935% above its historical low of 0.02x in Feb 2020. Over the past 12 months, the PS ratio has expanded from ~0.6x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Aptevo Therapeutics Inc (APVO) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Aptevo Therapeutics Inc operates as a stable business with moderate growth and solid fundamentals. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.23 indicates a conservative balance sheet with 21M in cash.
Revenue contracted 100% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -7M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Aptevo Therapeutics Inc.
Bottom Line
Aptevo Therapeutics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Aptevo Therapeutics Inc(APVO)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company is headquartered in Seattle, Washington.